Why Are Statera Biopharma Shares Surging Today

  • Statera Biopharma Inc STAB has entered into a non-binding term sheet with Immune Therapeutics Inc IMUN to sell its naltrexone and met-enkephalin rights.
  • The transaction is contingent upon the negotiation of a definitive agreement and satisfaction of several closing conditions, including a contingency on Immune Therapeutics financing.
  • Under the anticipated terms, Statera will receive an initial $2 million upfront payment and 5% of the issued and outstanding stock of Immune Therapeutics. 
  • Also See: Coeptis Therapeutics Intends To Acquire Statera's TLR5 Agonist Platform.
  • Additionally, Statera will receive milestone-based payments. Potential indication payments will include asthma, multiple sclerosis, HIV, and chemotherapy. This transaction can generate over $400 million in non-dilutive payments to Statera.
  • Price Action: STAB shares are up 75.1% at $0.37 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!